BR112014016076A8 - peptídeo, vetor, contrução de peptídeo quimérico, ácido nucleico e uso dos mesmos e composição farmacêutica - Google Patents

peptídeo, vetor, contrução de peptídeo quimérico, ácido nucleico e uso dos mesmos e composição farmacêutica

Info

Publication number: BR112014016076A8
Authority: BR; Brazil
Prior art keywords: peptide; vector; construction; nucleic acid; pharmaceutical composition
Prior art date: 2011-12-27

Application number

BR112014016076A

Other languages

English (en)

Other versions

BR112014016076A2 (pt

BR112014016076B1 (pt

Inventor

Rebollo Garcia Angelita

Decaudin Didier

Nemati Fariba

Bravo Sicilia Jeronimo

Maria Fominaya Gutierrez Jesus

Original Assignee

Inst Curie

Univ Pierre Et Marie Curie Paris 6

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-27

Filing date

2012-12-27

Publication date

2017-07-04

2012-12-27 Application filed by Inst Curie, Univ Pierre Et Marie Curie Paris 6 filed Critical Inst Curie

2017-06-13 Publication of BR112014016076A2 publication Critical patent/BR112014016076A2/pt

2017-07-04 Publication of BR112014016076A8 publication Critical patent/BR112014016076A8/pt

2022-03-15 Publication of BR112014016076B1 publication Critical patent/BR112014016076B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22062—Caspase-9 (3.4.22.62)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Tropical Medicine & Parasitology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Hematology (AREA)
Dermatology (AREA)
Neurology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)

BR112014016076-7A 2011-12-27 2012-12-27 Peptídeo, vetor, construção de peptídeo quimérico e composição farmacêutica BR112014016076B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB11306784.7		2011-12-27
EP11306784		2011-12-27
PCT/EP2012/076968 WO2013098337A1 (en)	2011-12-27	2012-12-27	Cell-penetrating peptides

Publications (3)

Publication Number	Publication Date
BR112014016076A2 BR112014016076A2 (pt)	2017-06-13
BR112014016076A8 true BR112014016076A8 (pt)	2017-07-04
BR112014016076B1 BR112014016076B1 (pt)	2022-03-15

Family

ID=47553033

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112014016076-7A BR112014016076B1 (pt)	2011-12-27	2012-12-27	Peptídeo, vetor, construção de peptídeo quimérico e composição farmacêutica

Country Status (14)

Country	Link
US (2)	US9353155B2 (pt)
EP (1)	EP2797616B1 (pt)
JP (1)	JP6169606B2 (pt)
KR (1)	KR102071514B1 (pt)
CN (1)	CN104271147B (pt)
AU (1)	AU2012360845B2 (pt)
BR (1)	BR112014016076B1 (pt)
CA (1)	CA2859712C (pt)
DK (1)	DK2797616T3 (pt)
ES (1)	ES2748937T3 (pt)
IL (1)	IL233280B (pt)
PL (1)	PL2797616T3 (pt)
SG (2)	SG11201403683PA (pt)
WO (1)	WO2013098337A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2797617B1 (en) *	2011-12-27	2020-01-22	Sorbonne Université	Anti-tumor adjuvant therapy
EP3016972A2 (en) *	2013-07-03	2016-05-11	Université Pierre et Marie Curie (Paris 6)	Pro-apoptotic ras and raf peptides
EP2868326A1 (en)	2013-11-04	2015-05-06	Université Pierre et Marie Curie (Paris 6)	Peptide inhibitors of TEAD/YAP-TAZ interaction
EP2881472A1 (en) *	2013-12-09	2015-06-10	Université Pierre et Marie Curie (Paris 6)	A method of predicting a response to an anti-tumor treatment
JP6551825B2 (ja) *	2014-02-10	2019-07-31	公立大学法人首都大学東京	クロマチン構造制御剤
CN105315348B (zh) *	2014-06-23	2018-10-16	天津药物研究院	一种穿膜多肽及其制备方法和用途
KR101835554B1 (ko)	2014-06-24	2018-04-19	서울대학교 산학협력단	C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법
EP3277804A1 (en) *	2015-03-31	2018-02-07	Université Pierre et Marie Curie - Paris 6 (UPMC)	Pro-apoptotic set and pp2a peptides
CN105418733A (zh) *	2015-06-23	2016-03-23	天津药物研究院有限公司	一种穿膜多肽与抗肿瘤药偶联物的制备及应用
JP6958913B2 (ja)	2015-11-06	2021-11-02	ザボードオブトラスティーズオブザユニヴァーシティオブイリノイＴｈｅＢｏａｒｄＯｆＴｒｕｓｔｅｅｓＯｆＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＩｌｌｉｎｏｉｓ	心停止の処置のためのペプチドおよび方法
EP3272768A1 (en) *	2016-07-22	2018-01-24	Université Pierre et Marie Curie (Paris 6)	Chimeric peptides useful in malaria prophylaxis or treatment
CA3086387A1 (en)	2016-12-22	2018-06-28	Sorbonne Universite	Cell penetrating peptides with improved internalization properties
IL305820A (en) *	2017-02-19	2023-11-01	Nat Inst Biotechnology Negev Ltd	Peptide kinase inhibitors and methods of using them
WO2018156892A1 (en)	2017-02-23	2018-08-30	Adrx, Inc.	Peptide inhibitors of transcription factor aggregation
CN106995487B (zh) *	2017-04-17	2019-12-03	扬州大学	源于鸡传染性贫血病毒VP1-aa 23-43多肽作为高效细胞穿膜肽的应用
CN106831957B (zh) *	2017-04-17	2019-12-03	扬州大学	一种源于鸡传染性贫血病毒VP1-aa 1-19多肽作为高效细胞穿膜肽的应用
CN110997693A (zh)	2017-06-07	2020-04-10	阿德克斯公司	τ聚集抑制剂
EP3668886A2 (en)	2017-08-18	2020-06-24	Adrx, Inc.	Tau aggregation peptide inhibitors
JP7072381B2 (ja)	2017-12-21	2022-05-20	株式会社クボタ	コンバイン制御システム
CN111729070B (zh) *	2020-06-02	2021-03-30	遵义医科大学珠海校区	多肽fl15在制备抗肿瘤药物中的应用
WO2023017976A1 (ko) *	2021-08-09	2023-02-16	주식회사 쎌트로이	양이온성 세포 투과성 펩타이드 및 이의 용도
CN115028685B (zh) *	2022-06-24	2023-10-20	张金强	一种阳离子双环抗菌肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5468223A (en)	1992-11-30	1995-11-21	C.N.R.S. Paris	Electrochemotherapy
FR2827866B1 (fr)	2001-07-27	2004-12-10	Pasteur Institut	Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
WO2004011595A2 (fr) *	2002-07-26	2004-02-05	Institut Pasteur	Vecteurs destines au transfert de molecules d'interet dans des cellules cibles
WO2006124537A1 (en) *	2005-05-12	2006-11-23	The Burnham Institute	Compounds that regulate apoptosis
US20070184015A1 (en)	2006-02-03	2007-08-09	Soonkap Hahn	Novel PEGylation agent
CN101412747B (zh) *	2008-10-21	2011-04-20	中国药科大学	新型穿膜肽及其用途
EP2236603A1 (en)	2009-03-30	2010-10-06	Universite Pierre Et Marie Curie	Pro-apoptotic peptides
EP2797617B1 (en) *	2011-12-27	2020-01-22	Sorbonne Université	Anti-tumor adjuvant therapy

2012
- 2012-12-27 CA CA2859712A patent/CA2859712C/en active Active
- 2012-12-27 ES ES12813376T patent/ES2748937T3/es active Active
- 2012-12-27 US US14/366,199 patent/US9353155B2/en active Active
- 2012-12-27 CN CN201280065370.2A patent/CN104271147B/zh active Active
- 2012-12-27 BR BR112014016076-7A patent/BR112014016076B1/pt active IP Right Grant
- 2012-12-27 PL PL12813376T patent/PL2797616T3/pl unknown
- 2012-12-27 SG SG11201403683PA patent/SG11201403683PA/en unknown
- 2012-12-27 AU AU2012360845A patent/AU2012360845B2/en active Active
- 2012-12-27 DK DK12813376.6T patent/DK2797616T3/da active
- 2012-12-27 WO PCT/EP2012/076968 patent/WO2013098337A1/en active Application Filing
- 2012-12-27 SG SG10201607271SA patent/SG10201607271SA/en unknown
- 2012-12-27 KR KR1020147021107A patent/KR102071514B1/ko active IP Right Grant
- 2012-12-27 EP EP12813376.6A patent/EP2797616B1/en active Active
- 2012-12-27 JP JP2014549469A patent/JP6169606B2/ja active Active
2014
- 2014-06-19 IL IL233280A patent/IL233280B/en active IP Right Grant
2016
- 2016-05-26 US US15/165,754 patent/US9644001B2/en active Active

Also Published As

Publication number	Publication date
US9644001B2 (en)	2017-05-09
DK2797616T3 (da)	2019-10-07
IL233280A0 (en)	2014-08-31
KR20140128971A (ko)	2014-11-06
BR112014016076A2 (pt)	2017-06-13
US9353155B2 (en)	2016-05-31
JP2015504050A (ja)	2015-02-05
IL233280B (en)	2019-08-29
JP6169606B2 (ja)	2017-07-26
WO2013098337A1 (en)	2013-07-04
PL2797616T3 (pl)	2020-03-31
KR102071514B1 (ko)	2020-01-30
ES2748937T3 (es)	2020-03-18
AU2012360845A1 (en)	2014-07-31
EP2797616A1 (en)	2014-11-05
SG11201403683PA (en)	2014-10-30
CA2859712C (en)	2023-09-19
SG10201607271SA (en)	2016-10-28
CN104271147A (zh)	2015-01-07
CA2859712A1 (en)	2013-07-04
US20160257713A1 (en)	2016-09-08
CN104271147B (zh)	2018-01-12
US20140364376A1 (en)	2014-12-11
BR112014016076B1 (pt)	2022-03-15
EP2797616B1 (en)	2019-07-31
AU2012360845B2 (en)	2017-05-11

Publication	Publication Date	Title
BR112014016076A8 (pt)	2017-07-04	peptídeo, vetor, contrução de peptídeo quimérico, ácido nucleico e uso dos mesmos e composição farmacêutica
BR112013033350A2 (pt)	2017-01-31	imunocitocina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
BR112012024287A2 (pt)	2017-03-01	anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
BRPI1007005A2 (pt)	2016-03-22	anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6
DK3578659T3 (da)	2024-02-05	Kunstige nukelinsyremolekyler til forbedret protein- eller peptidekspression
DK3238709T3 (da)	2020-09-28	Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
BR112014021103A8 (pt)	2018-01-23	anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BR112014001991A2 (pt)	2017-02-21	certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos
BR112014013760A2 (pt)	2017-06-13	composto, composição farmacêutica e uso de um composto
BR112014022788A2 (pt)	2017-11-14	peptídeo, polipeptídeos, ácido nucleico, composição farmacêutica, conjugado e método in vitro
BR112013011448A2 (pt)	2016-08-09	composto, composição farnmacêutica, e, uso do composto
BR112014014078A8 (pt)	2017-06-13	composições compreendendo constructos genéticos il-12 aperfeiçoados e vacinas, imunoterapêuticos e métodos de uso dos mesmos
BR112014012005A2 (pt)	2017-12-19	composições, métodos, formulação farmacêutica e artigo
BR112013020368A2 (pt)	2017-09-19	peptídeos modificados hidrofóbicos e uso dos mesmos para alvo específico no fígado
BR112014005669A2 (pt)	2017-04-04	composto, composição farmacêutica e uso de um composto
CO7020907A2 (es)	2014-08-11	Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
BR112013014644A2 (pt)	2017-03-07	composição farmacêutica e complexo
BR112014003567A2 (pt)	2018-08-14	composto, uso de um composto, e, composição farmacêutica
BR112014010290A2 (pt)	2017-05-02	composição farmacêutica, métodos, composições e usos
BR112013030824A2 (pt)	2016-12-06	bactéria gram-positiva, ácido necleico recombinante, composição farmacêutica e vetor
BR112014017518A8 (pt)	2017-07-04	anticorpo e ácido nucleico isolados, célula hospedeira, métodos, imunoconjugado, formulação farmacêutica e uso do anticorpo
BR112015011111A2 (pt)	2017-11-14	proteína multifuncional e formulação farmacêutica
BR112012031226A2 (pt)	2018-03-06	composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BR112014004936A2 (pt)	2017-04-04	polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo
BR112013030395A2 (pt)	2016-12-13	polipeptídeo, polinucleotídeo, vetor, composição imunogênica, vacina, e, uso de uma composição imunogênica

Legal Events

Date	Code	Title	Description
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2019-09-17	B25A	Requested transfer of rights approved	Owner name: INSTITUT CURIE (FR) ; SORBONNE UNIVERSITE (FR)
2019-10-15	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-10-29	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-05-11	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-06-01	B350	Update of information on the portal [chapter 15.35 patent gazette]
2021-12-28	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-03-15	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/12/2012, OBSERVADAS AS CONDICOES LEGAIS.